BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IsoTis OrthoBiologics Appoints Former Opus Medical CEO To Board Of Directors


10/19/2005 5:09:22 PM

LAUSANNE, Switzerland and IRVINE, California, June 27 /PRNewswire-FirstCall/ -- IsoTis OrthoBiologics today announced the appointment of James (Jim) Hart to the Board of Directors at its recent annual general shareholders meeting.

Jim Hart brings a wealth of executive management experience in strategic marketing, distribution and M&A in the orthopaedics industry. Mr. Hart has worked in the orthopaedics industry for approximately 20 years, including a 12 year tenure at Zimmer Holdings, Inc., one of the leading global orthopaedic companies, where his last position was Vice President Strategic Marketing. Earlier this year Mr. Hart concluded the sale of sports medicine company Opus Medical Inc., where he was President, CEO, and Director, to ArthroCare Corporation.

In addition, the shareholders meeting appointed Pieter Wolters to the Board of Directors. Mr. Wolters has been with the company since 1997, and has served as its CEO since July 1, 2004. Directors Aart Brouwer and Henjo Hielkema were re-appointed to the Board for a period of three years.

The shareholders meeting also authorized the Board of Directors to increase the share capital by a maximum of 7.8 million registered shares at its discretion for potential corporate transactions.

Pieter Wolters, President and CEO of IsoTis OrthoBiologics, said: "Board and Management are very pleased with the continued support of our shareholders, and welcome Jim Hart to our Board of Directors. Jim has an impressive track record in the orthopaedics industry by any standard, and with his long experience in both hands-on and strategic issues will be an extremely valuable resource for us to draw on. "

IsoTis OrthoBiologics has a product portfolio with several highly innovative and proprietary natural and synthetic bone graft substitutes on the market and several others in development, orthobiology sales of over US$ 25 million in 2004, an established North American independent distribution network, and a rapidly expanding international presence. The company's main commercial operations are based out of Irvine, CA; its international sales headquarters is based in Lausanne, Switzerland.

Certain statements in this Press Release are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as 'strategy,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'will,' 'continues,' 'estimates,' 'intends,' 'projects,' 'goals,' 'targets' and other words of similar meaning are intended to identify such forward-looking statements. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such statements are based on the current expectations of the management of IsoTis S.A. only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of IsoTis. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting IsoTis' business, including but not limited to the timely commencement and success of IsoTis' clinical trials and research endeavors, delays in receiving U.S. FDA or other regulatory approvals (a.o. EMEA, CE), market acceptance of the Company's products, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet conditions imposed for the required governmental and regulatory approvals and consents. IsoTis expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting IsoTis, refer to the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2004, filed with the SEC and to IsoTis' reports filed from time to time with the Swiss Stock Exchange (SWX), Euronext Amsterdam N.V., and SEDAR at www.sedar.com, as well as the Toronto Stock Exchange (TSX).

IsoTis OrthoBiologics

CONTACT: Hans Herklots, Director IR, Tel: +41-(0)21-620-6011, E-mail:hans.herklots@isotis.com; Rob Morocco, CFO, +1-949-855-7158,rob.morocco@isotis.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES